MR imaging of the small bowel with increasing concentrations of an oral osmotic agent

Abstract

The aim of this study was to assess the quality of MR imaging and level of adverse effects with increasing concentrations of gastrografin. This is a prospective study with 24 healthy volunteers which were randomised into four groups receiving 50%, 25%, 10% and 0% gastrografin. The endpoint was bowel image quality based on distension, signal homogeneity and wall delineation evaluated by three independent radiologists, and the maximum bowel diameter at three different levels. The subjects also scored any adverse events on a 1-5 scale. The interradiologist agreement was relatively good, with kappa values varying between 0.81 and 0.41. Improved bowel distension and image quality were achieved with increasing concentrations. But significant dose-response effects were found between increasing osmolalities and the bowel diameters and also versus the score of adverse events. The most frequent adverse reactions were diarrhea, nausea and lack of palatability. There is a gradient relationship between increasing osmolality of gastrografin and improved image quality and the score of adverse effects. The optimum concentration of gastrografin is dependent of the tolerance of the adverse events.

Assessment of Crohn’s disease in the small bowel: prospective comparison of magnetic resonance enteroclysis with conventional enteroclysis

“…Several new contrast agents for MR imaging of the gastrointestinal tract have been proposed and are classified as positive, negative, or biphasic [30,31]. Because MR fluoroscopy is a heavily T2-weighted sequence the contrast medium for MR enteroclysis must have high signal intensity on T2-weighted images.…”

Diagnostic performance of MRI for detection of intestinal fistulas in patients with complicated inflammatory bowel conditions

“…That is why we did without, while relying on the relaxing effect of the i.v. injected antiperistaltic agent, as reported previously [22,23].…”

MR enterography in Crohn’s disease: current consensus on optimal imaging technique and future advances from the SAR Crohn’s disease-focused panel

“…As a general rule, as the osmolality of the agent increases, the side effects (nausea, diarrhea, and flatulence) increase and the palatability decreases [16,17]. Commonly used agents include 0.1% low-density barium sulfate suspension (VoLumen, E-Z-EM, NY), as well as polyethylene glycol and methylcellulose.…”